Job Description:

Title: Go-To-Market Manager
Team: AI Demand Generation
Location: Remote EST or CST (US or Canada)

Why This Role Exists

Phreesia’s demand generation engine is AI-native at its core and operates at the frontier of how B2B demand generation is evolving. Campaigns are identified, briefed, and orchestrated through a Claude-powered marketing repository, with personalization at scale driven by tools like Artisan, 6Sense, Marketo, and Qualified.

As Go-To-Market Manager, you’re the operator inside that system — owning the execution of targeted, multi-channel campaigns that drive revenue across both new prospective and existing accounts. You’ll work at the intersection of data, messaging, and revenue: partnering with SDRs, Sales, and Product to build campaigns with a defined right to win, coordinating execution across email, paid media, AI outreach, and SDR motions, and using performance signals to continuously sharpen what works.

You’ll sit on the AI Demand Generation team under Joe Adams, in a highly coordinated, insight-driven environment where the expectation is proactive ownership, analytical rigor, and creative execution.

What You’ll Spend Your Time Doing

Own campaign strategy and execution.
Own the end-to-end execution of time-boxed, multi-channel campaigns targeting defined account segments across net-new and base motions. Translate segments and intent data into a coherent campaign brief — including right to win, messaging framework, channel plan, and timeline — and coordinate parallel build tracks so campaigns launch on schedule and on message.
Bring new products and solutions to market.
Act as a strategic operator for new product and solution launches, crafting go-to-market narratives and execution plans that accelerate adoption and revenue.
Create content and messaging that cuts through.
Develop client- and prospect-facing content that resonates with target personas and drives engagement, including emails, landing pages, ad copy, and SDR talk tracks. Translate common client business challenges into campaign narratives that create urgency and relevance.
Build personalization into every touchpoint.
Work with the AI SDR platform, Artisan, and the Demand Gen repo to keep messaging consistent and personalized across every touchpoint.
Coordinate across revenue teams.
Serve as the coordination point between Demand Gen, SDR teams, Sales, and Client Success so everyone works the same accounts with aligned messaging. Brief the Priority SDR team on campaign context, segment rationale, and talk tracks so outbound reinforces digital touchpoints.
Partner on campaign infrastructure and targeting.
Partner with Marketing Operations on Marketo builds, lead routing, and campaign tracking in Salesforce, and with ABM and Field Marketing on account targeting.
Turn performance signals into action.
Track leading indicators, including intent creation, MQL/MQC volume, and opportunity creation, as well as lagging indicators such as expected-value qualified pipeline influenced. Analyze results at campaign close, codify learnings, and feed them back into the Demand Gen repo to improve future campaigns and the always-on motion.
Continuously sharpen what works.
Identify underperforming segments or channels and drive iterative improvements to messaging, sequencing, or targeting. Use 6Sense signals to adjust priorities as accounts progress.

What Makes You a Great Fit

You don’t need to check every box — but this role will feel energizing if you:

Communicate with precision and can make a clear, confident case — in writing, in a room, or in a deck — calibrated to the audience.
Know how to own GTM from idea to revenue, driving launches and campaigns end-to-end from the first brief to the pipeline they generate.
Move quickly from insight to action and don’t let ambiguity or process slow you down.
Read the business through data and are comfortable identifying what matters in the numbers, what it means, and what to do about it.
Find the unexpected angle, using the obvious answer as a starting point and developing approaches and campaigns that stand out.
Bring intellectual curiosity and actively look for a better way — including when it means changing your own approach.
Set and charge at audacious goals, executing with urgency toward ambitious outcomes.
Know which details are load-bearing and give them the attention they deserve without losing speed elsewhere.
Bring relentless follow-through and deliver on commitments without needing reminders.
Have hands-on experience with marketing automation such as Marketo, CRM platforms such as Salesforce, ABM platforms such as 6Sense or Demandbase, and AI-powered outreach tools such as Artisan, Clay, Qualified, or equivalents.
Have experience in healthcare SaaS or a similarly complex, long-cycle B2B environment.

We Do Have A Few Requirements To Check

Bachelor's degree and 5+ years of experience in B2B demand generation, campaign management, revenue marketing, or a GTM role.

Where You’ll Work

This is a fully remote role for candidates based in the EST or CST in the US or Canada.

Compensation & Rewards

Cash Compensation: $120,000-150,000 USD or CAD (depending on experience with opportunity for variable)
A comprehensive Total Rewards package designed to support your whole life — not just your work

Who We Are:

At Phreesia, we’re looking for smart and passionate people to help drive our mission of creating a better, more engaging healthcare experience. We’re committed to helping healthcare organizations succeed in an ever-evolving landscape by transforming the way healthcare is delivered. Our SaaS platform digitizes appointment check-in and offers tools to engage patients, improve efficiency, optimize staffing, and enhance clinical care.

Phreesia cares about our employees by providing a diverse and dynamic work environment. We’re a five-time winner of Modern Healthcare Magazine’s Best Places to Work in Healthcare award and we’ve been recognized on the Bloomberg Gender Equality Index. We are dedicated to continuously improving our employee experience by launching new programs and initiatives. If you thrive in a culture of recognition, value inclusivity, professional development, and growth opportunities, Phreesia could be a great fit!

Top-rated Employee Benefits:

100% Remote work + home office expense reimbursements
Competitive compensation
Flexible PTO + 8 company holidays
Monthly reimbursement for cell phone + internet + wellness
100% Paid 12-week parental leave to our U.S. employees, as well as a generous parental benefit to our employees in Canada
Variety of insurance coverage for people (and pets!)
Continuing education and professional certification reimbursement
Opportunity to join an Employee Resource Group. Learn more here: https://www.phreesia.com/workforce/

We strive to provide a diverse and inclusive environment and are an equal opportunity employer.

About the company

Phreesia provides a cloud-based patient intake platform for medical practices. It automates front-office tasks such as appointment scheduling, insurance verification, and payment processing, helping providers reduce paperwork and spend more time with patients. The platform also supports real-time patient surveys, clinical and behavioral health screenings, and data analytics. It integrates with leading EMR and Practice Management systems so patient data stays up to date across systems. Phreesia runs on a SaaS model with subscription fees, optional premium features, and transaction-based payment processing fees, plus charges for value-added services. Compared with competitors, it emphasizes seamless EMR/PM integration, automated end-to-end intake, and actionable insights from analytics to boost patient engagement and operational efficiency. The goal is to streamline administrative workflows, shorten wait times, and improve the overall patient experience in healthcare settings.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2005

Get referred to Phreesia

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2027 revenue reached $129.5 million, up 10%, with positive free cash flow.
The May 7, 2026 restructuring cut 220 roles and funded margin expansion.
July 23, 2026 March of Dimes partnership deepens patient engagement in maternal care.

What critics are saying

May 7, 2026 eliminated 220 positions, signaling demand for lasting cost cuts, not growth hiring.
Q2 2027 earnings missed consensus EPS by six cents, keeping Phreesia a hold-story.
Epic and athenahealth can bundle intake, compressing Phreesia's pricing power inside 24 months.

What makes Phreesia unique

Phreesia touches one in six U.S. patient visits, creating unmatched workflow distribution.
Its software sits inside intake, payments, surveys, and EMR integrations, locking daily operational usage.
ProviderConnect and DeepIntent audiences monetize clinical data beyond intake, expanding Phreesia's network effects.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options
Home Office Stipend
Phone/Internet Stipend
Wellness Program
Flexible Work Hours
Paid Holidays
Paid Vacation
Parental Leave
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

MyChesCo

Oct 18th, 2026

Phreesia executive earns recognition for healthcare leadership.

Phreesia executive earns recognition for healthcare leadership. WILMINGTON, DE - Phreesia executive Michael Rasbury has been named to Becker's Hospital Review's 2026 list of Rising Stars: Healthcare Leaders Under 40, recognizing his work overseeing patient financing operations and improving service delivery for healthcare organizations. Rasbury serves as vice president of AccessOne Solutions at Phreesia, where he manages approximately 80 employees supporting healthcare providers with patient payment arrangements, collections and cash flow management. His responsibilities include patient financial engagement, client implementation and operational performance as healthcare organizations seek to improve payment processes while offering patients flexible options for managing medical expenses. Discover more Local advertising services Community news subscription Local news updates Becker's Hospital Review selected its 2026 honorees through nominations and editorial research. The annual recognition identifies healthcare professionals younger than 40 who have demonstrated leadership in addressing industry challenges. Rasbury has worked at Phreesia for more than a decade, advancing from project manager to vice president. Before assuming leadership of AccessOne, he directed Phreesia's client services organization and managed consultants across the United States, Canada and India. During that period, he oversaw initiatives to improve implementation efficiency, reduce the time required to launch client projects and standardize onboarding procedures. Those efforts also focused on strengthening relationships with healthcare organizations and improving consistency during the implementation of Phreesia's services. "What motivates me is building teams and processes that help our clients succeed and make the financial side of healthcare easier for patients," Rasbury said. Phreesia provides technology for patient intake, outreach and engagement, while its AccessOne business focuses on patient financial services and payment management. Rasbury's recognition comes as he leads AccessOne's operational teams and efforts to improve the delivery of financial services to healthcare providers and their patients. Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources - free for everyone. If you value that, click here to become a patron today. Local advertising services Discover more Online newspaper access Pennsylvania travel guide

Business Insider

Oct 11th, 2026

Barclays reaffirms their Hold rating on Phreesia (PHR).

Barclays reaffirms their Hold rating on Phreesia (PHR). Oct. 11, 2026, 09:15 PM In a report released on October 9, Glen Santangelo from Barclays maintained a Hold rating on Phreesia, with a price target of $11.00. The company's shares closed last Friday at $10.81. According to TipRanks, Santangelo is a 4-star analyst with an average return of 3.8% and a 52.15% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Align Tech, and Cencora. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Phreesia with a $13.22 average price target. Based on Phreesia's latest earnings release for the quarter ending July 31, the company reported a quarterly revenue of $129.46 million and a net profit of $1.92 million. In comparison, last year the company earned a revenue of $117.26 million and had a net profit of $654 thousand Read More on PHR:

Phreesia

Sep 25th, 2026

Phreesia named one of TIME's World's Top HealthTech Companies 2026.

Phreesia named one of TIME's World's Top HealthTech Companies 2026. * Published - September 25, 2026 Making care easier - in its clients' words. More than 4,700 healthcare organizations use Phreesia to make care easier for patients, practices and staff. Here's what that looks like every day. "The patient impact is undeniable." Cassandra englund-thompson, strategic project consultant, summit orthopedics. Appointment Accelerator(R) offers canceled appointments to eligible patients automatically - helping people get care sooner while keeping schedules full, without adding work for staff. "Registration is revenue." Matthew moore, chief technology innovation officer, effingham health system. Accurate registration supports cleaner claims. Upfront eligibility checks catch issues earlier. And clear, convenient payment options help patients resolve balances sooner. "Payments, scheduling and refills are exactly where AI helps." Sneha Patel, CEO, COO, MPAS, PA-C, metroplex medical centres. "Instead of hiring more FTEs to do manual tasks, we're using technology to solve problems at scale," Patel said. "Phreesia was a strong partner for us from the beginning." Troy moore, CEO, Ellinwood hospital & clinic. Technology creates more value when it becomes a chance to improve how the organization operates. For Ellinwood, that meant involving the right people, looking beyond any one workflow and staying open to change. Making care easier every day. Today, Phreesia supports more than 180 million patient visits each year - about 1 in 6 visits across the U.S. Across its network, 85% of patients check themselves in, saving staff more than five minutes per self-service check-in. And 97% of patients report being satisfied with their Phreesia experience. For more than 20 years, Phreesia has focused on technology patients use, teams value and practices can build on. Phreesia is honored to be named one of TIME's World's Top HealthTech Companies 2026 - and excited to keep making care easier every day, for everyone. G2 Leader Capterra Shortlist KLAS Best in KLAS HITRUST CRF SOC 2 TYPE 2 The best-performing practices run on Phreesia. See what changes when your platform closes the loop - from first call to final payment.

MarketBeat

Sep 22nd, 2026

Insider selling: Phreesia (NYSE:PHR) General Counsel sells $67,152.96 in stock.

Insider selling: Phreesia (NYSE:PHR) General Counsel sells $67,152.96 in stock. September 22, 2026 Key points. * Phreesia General Counsel Allison Hoffman sold 6,662 shares at an average price of $10.08, generating $67,152.96. The Rule 10b5-1 sale covered tax withholding tied to vested equity awards and reduced her ownership by 2.44%. * Phreesia shares rose 0.7% to $10.11, giving the company a market capitalization of approximately $627 million. The stock remains well below its 52-week high of $25.00. * The company's latest quarterly revenue increased 10.4% year over year to $129.46 million, but earnings of $0.03 per share missed analyst expectations of $0.09. Analysts maintain a consensus Hold rating with a $14.00 price target. * Five stocks we like better than Phreesia. Phreesia, Inc. (NYSE:PHR - Get Free Report) General Counsel Allison Hoffman sold 6,662 shares of the company's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $10.08, for a total transaction of $67,152.96. Following the completion of the transaction, the general counsel directly owned 266,574 shares in the company, valued at $2,687,065.92. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Phreesia stock up 0.7%. Shares of NYSE:PHR traded up $0.07 during midday trading on Tuesday, hitting $10.11. 476,751 shares of the stock were exchanged, compared to its average volume of 1,449,417. The company has a market capitalization of $627.22 million, a PE ratio of 59.44 and a beta of 0.86. Phreesia, Inc. has a 52-week low of $7.77 and a 52-week high of $25.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.76 and a current ratio of 1.76. The business's fifty day simple moving average is $11.15 and its two-hundred day simple moving average is $10.32. Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, September 2nd. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.06). Phreesia had a return on equity of 5.22% and a net margin of 2.06%.The firm had revenue of $129.46 million during the quarter, compared to analyst estimates of $129.06 million. During the same period in the previous year, the company earned $0.01 earnings per share. The business's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, research analysts predict that Phreesia, Inc. will post 0.33 earnings per share for the current fiscal year. Wall Street analyst weigh in. PHR has been the topic of several recent research reports. Robert W. Baird raised their price objective on shares of Phreesia from $10.00 to $11.00 and gave the company a "neutral" rating in a research report on Friday, September 4th. Weiss Ratings cut shares of Phreesia from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, September 4th. Truist Financial increased their target price on shares of Phreesia from $11.00 to $12.00 and gave the stock a "hold" rating in a research report on Thursday, May 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $14.00 price target on shares of Phreesia in a research report on Monday, August 31st. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $19.00 price target on shares of Phreesia in a research note on Thursday, September 3rd. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $14.00. Discover more Portfolio Management Tools Research tools access Institutional investors weigh in on Phreesia. Several hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC increased its position in Phreesia by 1,119.8% during the first quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company's stock worth $27,000 after acquiring an additional 3,001 shares during the period. New York State Teachers Retirement System bought a new stake in Phreesia in the 1st quarter valued at $44,000. Rockefeller Capital Management L.P. boosted its holdings in Phreesia by 354.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock valued at $47,000 after purchasing an additional 2,149 shares during the period. Allworth Financial LP acquired a new stake in Phreesia in the 2nd quarter worth $58,000. Finally, Essential Partners LLC grew its position in Phreesia by 2,016.6% in the 1st quarter. Essential Partners LLC now owns 9,313 shares of the company's stock worth $78,000 after purchasing an additional 8,873 shares during the last quarter. 92.10% of the stock is owned by institutional investors. Phreesia company profile. Phreesia, Inc is a healthcare technology company that provides software and services designed to help healthcare organizations manage patient intake and engagement. Its platform digitizes administrative and clinical processes that traditionally rely on paper forms, manual data entry, and separate payment systems. The company's offerings include digital patient check-in and registration, insurance and demographic information collection, appointment-related communications, electronic forms and consent management, patient surveys, and payment processing. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Phreesia, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list. While Phreesia currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely. Continue following MarketBeat

Yahoo Finance

Sep 14th, 2026

Phreesia partners with DeepIntent to offer real-time clinician targeting through ProviderConnect audiences

Phreesia has partnered with DeepIntent to make its ProviderConnect audiences available in the DeepIntent Audience Marketplace. ProviderConnect enables healthcare marketers to reach clinicians based on cases they are likely to see in upcoming practice, rather than using broad-reach awareness campaigns. The service draws on real-world care insights from Phreesia's product ecosystem to inform clinicians about new clinical data, safety information, and treatment options whilst maintaining privacy. Phreesia enabled more than 180 million patient visits in 2025, representing one in six visits across the US. The partnership allows brands already using DeepIntent to access Phreesia's real-time audience solution, helping healthcare marketers deliver more personalised media to providers before treatment decisions are made.